Global Drug Discovery Informatics 麻豆原创 Insights, Forecast to 2029

Publication ID:

PB504230987

Publication Date:

May 29, 2023

Pages:

105

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

IT Services [2]

Computing & Electronics [3]

Description:

麻豆原创 Analysis and Insights: Global Drug Discovery Informatics 麻豆原创
The global Drug Discovery Informatics market is projected to grow from US$ 1 million in 2023 to US$ 1 million by 2029, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
The US & Canada market for Drug Discovery Informatics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Drug Discovery Informatics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Drug Discovery Informatics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Drug Discovery Informatics include IBM, Infosys, Thermo Fisher Scientific, Perkinelmer, 厂肠丑谤枚诲颈苍驳别谤, Dassault Syst猫mes, Charles River Laboratories, Selvita and Certara, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Drug Discovery Informatics market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Drug Discovery Informatics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Drug Discovery Informatics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drug Discovery Informatics revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Drug Discovery Informatics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Drug Discovery Informatics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including IBM, Infosys, Thermo Fisher Scientific, Perkinelmer, 厂肠丑谤枚诲颈苍驳别谤, Dassault Syst猫mes, Charles River Laboratories, Selvita and Certara, etc.
By Company
IBM
Infosys
Thermo Fisher Scientific
Perkinelmer
厂肠丑谤枚诲颈苍驳别谤
Dassault Syst猫mes
Charles River Laboratories
Selvita
Certara
GVK Biosciences
Collaborative Drug Discovery
Openeye Scientific Software
IO Informatics
Novo Informatics
Segment by Type
Software
Services
Segment by Application
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Drug Discovery Informatics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Discovery Informatics companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Discovery Informatics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Drug Discovery Informatics 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Software
1.2.3 Services
1.3 麻豆原创 by Application
1.3.1 Global Drug Discovery Informatics 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical & Biotechnology Companies
1.3.3 Contract Research Organizations (CROs)
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug Discovery Informatics 麻豆原创 Perspective (2018-2029)
2.2 Global Drug Discovery Informatics Growth Trends by Region
2.2.1 Drug Discovery Informatics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Drug Discovery Informatics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Drug Discovery Informatics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Drug Discovery Informatics 麻豆原创 Dynamics
2.3.1 Drug Discovery Informatics Industry Trends
2.3.2 Drug Discovery Informatics 麻豆原创 Drivers
2.3.3 Drug Discovery Informatics 麻豆原创 Challenges
2.3.4 Drug Discovery Informatics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Drug Discovery Informatics by Players
3.1.1 Global Drug Discovery Informatics Revenue by Players (2018-2023)
3.1.2 Global Drug Discovery Informatics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Drug Discovery Informatics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Drug Discovery Informatics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Drug Discovery Informatics 麻豆原创 Concentration Ratio
3.4.1 Global Drug Discovery Informatics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug Discovery Informatics Revenue in 2022
3.5 Global Key Players of Drug Discovery Informatics Head office and Area Served
3.6 Global Key Players of Drug Discovery Informatics, Product and Application
3.7 Global Key Players of Drug Discovery Informatics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug Discovery Informatics Breakdown Data by Type
4.1 Global Drug Discovery Informatics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Drug Discovery Informatics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Drug Discovery Informatics Breakdown Data by Application
5.1 Global Drug Discovery Informatics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Drug Discovery Informatics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Drug Discovery Informatics 麻豆原创 Size (2018-2029)
6.2 North America Drug Discovery Informatics 麻豆原创 Size by Type
6.2.1 North America Drug Discovery Informatics 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Drug Discovery Informatics 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Drug Discovery Informatics 麻豆原创 Share by Type (2018-2029)
6.3 North America Drug Discovery Informatics 麻豆原创 Size by Application
6.3.1 North America Drug Discovery Informatics 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Drug Discovery Informatics 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Drug Discovery Informatics 麻豆原创 Share by Application (2018-2029)
6.4 North America Drug Discovery Informatics 麻豆原创 Size by Country
6.4.1 North America Drug Discovery Informatics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Drug Discovery Informatics 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Drug Discovery Informatics 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Drug Discovery Informatics 麻豆原创 Size (2018-2029)
7.2 Europe Drug Discovery Informatics 麻豆原创 Size by Type
7.2.1 Europe Drug Discovery Informatics 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Drug Discovery Informatics 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Drug Discovery Informatics 麻豆原创 Share by Type (2018-2029)
7.3 Europe Drug Discovery Informatics 麻豆原创 Size by Application
7.3.1 Europe Drug Discovery Informatics 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Drug Discovery Informatics 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Drug Discovery Informatics 麻豆原创 Share by Application (2018-2029)
7.4 Europe Drug Discovery Informatics 麻豆原创 Size by Country
7.4.1 Europe Drug Discovery Informatics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Drug Discovery Informatics 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Drug Discovery Informatics 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Drug Discovery Informatics 麻豆原创 Size (2018-2029)
8.2 China Drug Discovery Informatics 麻豆原创 Size by Type
8.2.1 China Drug Discovery Informatics 麻豆原创 Size by Type (2018-2023)
8.2.2 China Drug Discovery Informatics 麻豆原创 Size by Type (2024-2029)
8.2.3 China Drug Discovery Informatics 麻豆原创 Share by Type (2018-2029)
8.3 China Drug Discovery Informatics 麻豆原创 Size by Application
8.3.1 China Drug Discovery Informatics 麻豆原创 Size by Application (2018-2023)
8.3.2 China Drug Discovery Informatics 麻豆原创 Size by Application (2024-2029)
8.3.3 China Drug Discovery Informatics 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Drug Discovery Informatics 麻豆原创 Size (2018-2029)
9.2 Asia Drug Discovery Informatics 麻豆原创 Size by Type
9.2.1 Asia Drug Discovery Informatics 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Drug Discovery Informatics 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Drug Discovery Informatics 麻豆原创 Share by Type (2018-2029)
9.3 Asia Drug Discovery Informatics 麻豆原创 Size by Application
9.3.1 Asia Drug Discovery Informatics 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Drug Discovery Informatics 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Drug Discovery Informatics 麻豆原创 Share by Application (2018-2029)
9.4 Asia Drug Discovery Informatics 麻豆原创 Size by Region
9.4.1 Asia Drug Discovery Informatics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Drug Discovery Informatics 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Drug Discovery Informatics 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Drug Discovery Informatics 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 IBM
11.1.1 IBM Company Details
11.1.2 IBM Business Overview
11.1.3 IBM Drug Discovery Informatics Introduction
11.1.4 IBM Revenue in Drug Discovery Informatics Business (2018-2023)
11.1.5 IBM Recent Developments
11.2 Infosys
11.2.1 Infosys Company Details
11.2.2 Infosys Business Overview
11.2.3 Infosys Drug Discovery Informatics Introduction
11.2.4 Infosys Revenue in Drug Discovery Informatics Business (2018-2023)
11.2.5 Infosys Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Details
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Drug Discovery Informatics Introduction
11.3.4 Thermo Fisher Scientific Revenue in Drug Discovery Informatics Business (2018-2023)
11.3.5 Thermo Fisher Scientific Recent Developments
11.4 Perkinelmer
11.4.1 Perkinelmer Company Details
11.4.2 Perkinelmer Business Overview
11.4.3 Perkinelmer Drug Discovery Informatics Introduction
11.4.4 Perkinelmer Revenue in Drug Discovery Informatics Business (2018-2023)
11.4.5 Perkinelmer Recent Developments
11.5 厂肠丑谤枚诲颈苍驳别谤
11.5.1 厂肠丑谤枚诲颈苍驳别谤 Company Details
11.5.2 厂肠丑谤枚诲颈苍驳别谤 Business Overview
11.5.3 厂肠丑谤枚诲颈苍驳别谤 Drug Discovery Informatics Introduction
11.5.4 厂肠丑谤枚诲颈苍驳别谤 Revenue in Drug Discovery Informatics Business (2018-2023)
11.5.5 厂肠丑谤枚诲颈苍驳别谤 Recent Developments
11.6 Dassault Syst猫mes
11.6.1 Dassault Syst猫mes Company Details
11.6.2 Dassault Syst猫mes Business Overview
11.6.3 Dassault Syst猫mes Drug Discovery Informatics Introduction
11.6.4 Dassault Syst猫mes Revenue in Drug Discovery Informatics Business (2018-2023)
11.6.5 Dassault Syst猫mes Recent Developments
11.7 Charles River Laboratories
11.7.1 Charles River Laboratories Company Details
11.7.2 Charles River Laboratories Business Overview
11.7.3 Charles River Laboratories Drug Discovery Informatics Introduction
11.7.4 Charles River Laboratories Revenue in Drug Discovery Informatics Business (2018-2023)
11.7.5 Charles River Laboratories Recent Developments
11.8 Selvita
11.8.1 Selvita Company Details
11.8.2 Selvita Business Overview
11.8.3 Selvita Drug Discovery Informatics Introduction
11.8.4 Selvita Revenue in Drug Discovery Informatics Business (2018-2023)
11.8.5 Selvita Recent Developments
11.9 Certara
11.9.1 Certara Company Details
11.9.2 Certara Business Overview
11.9.3 Certara Drug Discovery Informatics Introduction
11.9.4 Certara Revenue in Drug Discovery Informatics Business (2018-2023)
11.9.5 Certara Recent Developments
11.10 GVK Biosciences
11.10.1 GVK Biosciences Company Details
11.10.2 GVK Biosciences Business Overview
11.10.3 GVK Biosciences Drug Discovery Informatics Introduction
11.10.4 GVK Biosciences Revenue in Drug Discovery Informatics Business (2018-2023)
11.10.5 GVK Biosciences Recent Developments
11.11 Collaborative Drug Discovery
11.11.1 Collaborative Drug Discovery Company Details
11.11.2 Collaborative Drug Discovery Business Overview
11.11.3 Collaborative Drug Discovery Drug Discovery Informatics Introduction
11.11.4 Collaborative Drug Discovery Revenue in Drug Discovery Informatics Business (2018-2023)
11.11.5 Collaborative Drug Discovery Recent Developments
11.12 Openeye Scientific Software
11.12.1 Openeye Scientific Software Company Details
11.12.2 Openeye Scientific Software Business Overview
11.12.3 Openeye Scientific Software Drug Discovery Informatics Introduction
11.12.4 Openeye Scientific Software Revenue in Drug Discovery Informatics Business (2018-2023)
11.12.5 Openeye Scientific Software Recent Developments
11.13 IO Informatics
11.13.1 IO Informatics Company Details
11.13.2 IO Informatics Business Overview
11.13.3 IO Informatics Drug Discovery Informatics Introduction
11.13.4 IO Informatics Revenue in Drug Discovery Informatics Business (2018-2023)
11.13.5 IO Informatics Recent Developments
11.14 Novo Informatics
11.14.1 Novo Informatics Company Details
11.14.2 Novo Informatics Business Overview
11.14.3 Novo Informatics Drug Discovery Informatics Introduction
11.14.4 Novo Informatics Revenue in Drug Discovery Informatics Business (2018-2023)
11.14.5 Novo Informatics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

IBM
Infosys
Thermo Fisher Scientific
Perkinelmer
厂肠丑谤枚诲颈苍驳别谤
Dassault Syst猫mes
Charles River Laboratories
Selvita
Certara
GVK Biosciences
Collaborative Drug Discovery
Openeye Scientific Software
IO Informatics
Novo Informatics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.